\
&
Contact us
Published on | 11 months ago
ProgrammesDuring the past months, the Commission has published updated versions of several key documents for application to the call topics of the main Horizon Europe Work Programme (WP) 2025:
The updates mostly relate to cross-cutting principles of the programme which stakeholders need to take into account when developing a proposal. Therefore, it is important for (potential) applicants to read these key documents carefully and to make sure you are aware of the changes introduced by the Commission. Herewith an overview:
Important notice: the only correct application form is the one connected to the call topic you will apply to, which is available in the submission system. This may differ from the information in the standard application form.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Culture and society EIT New European Bauhaus
EIT Culture & Creativity has opened its first funding calls as an implementing partner of the New European Bauhaus (NEB) Academy, the learning and innovation infrastructure of the NEB. These two calls offer a total of €6 million to support circular fashion and skills development for the transformation of Europe’s lived environme... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.